Compare NiSource Inc Common Stock (NI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NiSource Inc Common Stock vs Organon & Co. Common Stock — how do they compare? NiSource Inc Common Stock trades at $41.35 (market cap $19.90B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: NiSource Inc Common Stock is far larger — about 5.5× Organon & Co. Common Stock's market cap, and NiSource Inc Common Stock pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold NiSource Inc Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| NI | OGN | |
|---|---|---|
Market Cap | $19.90B | $3.62B |
Volume | 3,295,580 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $49.08 | $13.81 |
52-Week Low | $39.00 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $37.23B | $11.04B |
Dividend Yield | 2.89% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NiSource (NI) trades at $41.49, up 0.63% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28, 2026. Fundamentals show solid profitability with a 13.15% net income margin and a P/E of 22.07. Recent news highlights dividend declarations and institutional buying interest, though the stock faces headwinds from storm recovery costs and interest rate sensitivity.
The outlook remains positive given analyst consensus with a $49.57 price target and 73% buy ratings. Key opportunities include data center demand growth and regulatory support, while risks involve volatile cash flows, high debt levels, and potential earnings pressure from operational disruptions. Investors should weigh the stable dividend yield against execution risks in a rising rate environment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NiSource Inc Common Stock
NiSource is an energy holding company whose regulated subsidiaries provide natural gas and electricity services. Its business is organized around gas distribution and electric operations in the United States.
Read more on NI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
